Advertisement
Table 4 Changes in metabolic tumor activity for the VOIman during the neoadjuvant treatment between the serial 18F-FDG PET-CT scans
| Parameter | Scan 1 vs. 2 | Scan 2 vs. 3 | Scan 1 vs. 3 | |||
|---|---|---|---|---|---|---|
| Δ | Δ % | Δ | Δ % | Δ | Δ % | |
| SUVmax | − 2.6 (− 6.4 to − 0.5)# | − 37.7 (− 67.7 to − 16.4) | − 0.3 (− 0.5 to − 0.1) | − 13.6 (− 17.5 to − 4.7) | − 3.2 (− 6.7 to − 0.5)# | − 41.6 (− 73.5 to − 27.7) |
| SUVpeak | −2.8 (− 5.6 to − 0.4)# | − 45.8 (− 67.4 to − 17.3) | − 0.2 (− 0.5 to 0.0) | − 9.3 (− 16.8 to 0.4) | − 2.9 (− 5.9 to − 0.3)# | − 45.1 (− 74.4 to − 21.9) |
| SUVmean | − 0.9 (− 1.9 to − 0.1)# | − 39.3 (− 52.0 to − 13.2) | − 0.1 (− 0.2 to 0.0) | − 4.6 (− 17.2 to 2.3) | − 1.0 (− 2.3 to − 0.2)# | − 44.1 (− 57.2 to − 17.0) |
| TLG | − 233.6 (− 637.9 to − 28.0)* | − 52.6 (− 73.6 to − 36.3) | − 18.4 (− 57.0 to − 10.6)# | − 16.3 (− 59.7 to − 5.5) | − 285.0 (− 714.7 to − 34.4)* | − 67.5 (− 82.6 to − 38.2) |
| MATV (ml) | − 22.1 (− 48.2 to 33.5) | − 7.5 (− 44.9 to 23.5) | − 13.2 (− 53.0 to − 5.3)# | − 19.8 (− 49.4 to − 2.7) | − 25.4 (− 70.6 to 27.6) | − 31.2 (− 67.2 to 3.8) |
